| Literature DB >> 26580591 |
Osama I Abd El-Salam1, Ali S Alsayed2, Korany A Ali3, Ahmed A Abd Elwahab4, Abd El-Galil E Amr5, Hassan M Awad6,7.
Abstract
A series of novel benzosuberone derivatives were synthesized and evaluated as antimicrobial agents by using substituted benzosuberone derivatives 1a,b as starting materials. Treatment of 1a,b with phenyl isothiocyanate in dimethylformamide was followed by treatment with cold HCl solution to afford the thioamides 4a,b, which was reacted with methyl iodide to obtain methylated products 5a,b. Cyclocondensation of 4a,b with chloroacetone 6 and phenacyl chloride 7 gave the corresponding thiophene derivatives 9a-c. Reaction of 4a,b with C-acetyl-N- arylhydrazonoyl chlorides 14a and 14b in boiling EtOH in the presence of triethylamine, afforded the corresponding 1,3,4-thiadiazoline derivatives 16a-d. The thioamides 4a,b were reacted with C-ethoxycarbonyl-N-arylhydrazonoyl chlorides 18a,b which afforded 1,3,4-thiadiazoline derivatives 19a-d. The benzosuberones 1a,b were treated with 3-mercaptopropanoic acid to give compounds 21a,b, which were cyclized to tricyclic thiopyran-4(5H)-one derivatives 22a,b. The latter compounds 22a,b were reacted with 3-mercaptopropanoic acid to give compounds 23a,b, which were cyclized tetracyclic ring systems 24a,b. Finally, compounds 24a,b were oxidized using hydrogen peroxide under reflux conditions to afford the oxidized form of the novel tetracyclic heterogeneous ring systems 25a,b. The newly synthesized compounds were screened for antimicrobial activities. The structures of new compounds were characterized by ¹H-NMR, 13C-NMR, IR, and EI-MS.Entities:
Keywords: antimicrobial activity; benzosuberone; nitro-benzosuberone; thiadiazole; thioamide; thiophene
Mesh:
Substances:
Year: 2015 PMID: 26580591 PMCID: PMC6332112 DOI: 10.3390/molecules201119701
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthetic routes for compounds 4a,b and 5a,b.
Scheme 2Synthetic routes for compounds 9a–c.
Scheme 3Mechanism of formation compound 9a.
Scheme 4Synthetic routes for compounds 16a–d.
Scheme 5Synthetic route for compounds 19a–d.
Scheme 6Synthetic routes for compounds 21a,b and 22a,b.
Scheme 7Synthetic routes for compounds 24 and 25.
Antimicrobial activity of compounds at 10 mg/mL.
| Comp. No. | Bacteria | Fungi | |||||||
|---|---|---|---|---|---|---|---|---|---|
| G + ve | G − ve | unicellular | filamentous | ||||||
| A. niger | |||||||||
| 17 | 17 | 14 | 17 | 14 | 15 | 15 | 12 | 11 | |
| 15 | 15 | 12 | 15 | 12 | 13 | 00 | 20 | 18 | |
| 00 | 18 | 15 | 18 | 15 | 14 | 15 | 20 | 19 | |
| 00 | 12 | 11 | 12 | 11 | 12 | 15 | 20 | 15 | |
| 12 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | |
| 12 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | |
| 22 | 20 | 17 | 20 | 18 | 17 | 17 | 20 | 16 | |
| 20 | 16 | 14 | 16 | 14 | 15 | 00 | 00 | 00 | |
| 12 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | |
| 15 | 15 | 13 | 15 | 12 | 13 | 00 | 00 | 00 | |
| 14 | 13 | 12 | 13 | 12 | 11 | 00 | 00 | 00 | |
| 12 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | |
| 22 | 20 | 17 | 20 | 17 | 18 | 17 | 00 | 00 | |
| 12 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | |
| 20 | 17 | 14 | 17 | 14 | 15 | 00 | 20 | 17 | |
| 17 | 15 | 13 | 15 | 12 | 13 | 20 | 00 | 00 | |
| 14 | 20 | 18 | 20 | 15 | 17 | 00 | 00 | 00 | |
| 25 | 00 | 00 | 00 | 00 | 00 | 30 | 40 | 20 | |
| 15 | 00 | 00 | 00 | 00 | 00 | 15 | 18 | 16 | |
| 15 | 00 | 00 | 00 | 00 | 00 | 15 | 18 | 15 | |
| 12 | 00 | 00 | 00 | 00 | 00 | 15 | 00 | 00 | |
| 17 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | |
| 27 | 25 | 19 | 25 | 19 | 20 | 25 | 29 | 20 | |
| S * =10 µg | 14 | 00 | 00 | 00 | 00 | 00 | 12 | 00 | 00 |
| TE * =30 µg | 10 | 00 | 00 | 00 | 00 | 00 | 23 | 00 | 00 |
| N * =30 µg | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 16 | 14 |
| T * =30 µg | 30 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 |
* S = Streptomycin; TE = Tetracycline; N = Neomycin and T = Oxytetracyciline.
Minimum inhibitory concentration (MIC) of different compounds against of tested pathogens.
| Comp. No. | Inhibition Zone Diameters (mm) | MIC (µg/mL) | ||||||
|---|---|---|---|---|---|---|---|---|
| 11 | 11 | 11 | 11 | 75 | 50 | 50 | 100 | |
| 11 | - | - | - | 100 | - | - | - | |
| 11 | - | - | - | 200 | - | - | - | |